Robertet SA header image

Robertet SA

RBT

Equity

ISIN FR0000039091 / Valor 510354

Euronext - Euronext Paris (2026-11-06)
EUR 830.00+0.61%

Robertet SA
UMushroom community rating:

star star star star star
0.00 0 votes No rating yet
NegativeNeutralPositive

About company

Robertet SA is a global company known for its expertise in providing natural flavors, fragrances, and ingredients for health and beauty products. With a focus on sustainability and organic raw materials, Robertet integrates all stages of the creative process from seed to release. The company's partnership with Sonarome, a family-owned company based in Bangalore, enhances its R&D capabilities and local market knowledge, further solidifying its position as an innovative and responsible leader in the industry.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results (04.11.2026):

Robertet SA — year ended December 31, 2025 (FY2025, corresponding to Q4 2025 year‑end): the Group reported revenue of €844 million with organic growth of 7.6% versus 2024, improved profitability (EBITDA up ~120 basis points) and attributable net income of €103.4 million (+15% year‑on‑year). The company continued targeted industrial and creative investments while citing currency and geopolitical headwinds; investments in 2025 totaled €44.2 million and equity stood at €602.5 million.

Top‑line & growth

Revenue: €844m in FY2025; organic revenue growth +7.6% vs 2024. Management highlights strong momentum across multiple divisions despite unfavorable currency moves.

Profitability

EBITDA expanded by about 120 basis points year‑on‑year and attributable net income rose 15% to €103.4m, indicating improved operating leverage and margin recovery in 2025.

Division performance

Raw Materials: +12.4% at constant rates; Fragrances: +2.1% like‑for‑like; Flavors: +10.4% at constant rates; Health & Beauty: +10.8% at constant rates. Flavors and Raw Materials were the strongest contributors to growth.

Investments & capacity

Industrial and IT investments totaled €44.2m in 2025. Major capacity/footprint moves included a new site in Karawang (Indonesia), spray‑drying in Bangalore (India), and modernization in Grasse; creative centers expanded globally.

Geographic & commercial moves

Expanded international presence with new subsidiaries (Australia, Poland) and additional creative centers (Shanghai, New York, Mexico, Dubai, Singapore), bringing the creative center network to 17 and 30 industrial sites overall.

Sustainability & supply chain

Robertet reaffirmed sustainability commitments: Platinum EcoVadis rating, SBTi roadmap launched in 2025, continued certification of strategic supply chains (examples: sandalwood, orange blossom, tonka bean). Environmental metrics cited include 0.53 t CO2 (Scope 1+2) per ton of product and 11% renewable energy of total consumption.

Balance sheet & people

Equity reported at €602.5m. Workforce ~2,700+ employees in 2025. Operational volumes: ~38,952 metric tons sold and 166,276 orders delivered.

Risks, headwinds & outlook

Management notes challenges from exchange‑rate volatility (weaker dollar/euro dynamics), geopolitical/customs constraints and some one‑off customer effects (e.g., US overstocking, tariff uncertainty). The group raised its 2030 revenue target earlier in 2025 and expects acceleration in 2026, particularly after restructuring in Health & Beauty and continued organic and acquisition‑driven growth.

Summarized from source with an LLMView Source

Key figures

0.61%1Y
7.37%3Y
-11.3%5Y

Performance

23.6%1Y
20.5%3Y
21.7%5Y

Volatility

Market cap

1826 M

Market cap (USD)

Daily traded volume (Shares)

543

Daily traded volume (Shares)

1 day high/low

862 / 853

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

0.00

0 votes
Performance:
starstarstarstarstar
0.00
Innovation:
starstarstarstarstar
0.00
Society:
starstarstarstarstar
0.00
Nature:
starstarstarstarstar
0.00

EQUITIES OF THE SAME SECTOR

Lupin Limited
Lupin Limited Lupin Limited Valor: 11598960
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.13%INR 1,990.00
ImmunityBio Inc
ImmunityBio Inc ImmunityBio Inc Valor: 110468647
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
7.80%USD 8.63
Astrana Health Inc
Astrana Health Inc Astrana Health Inc Valor: 28041888
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-11.56%USD 34.50
2invest AG
2invest AG 2invest AG Valor: 110098281
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.25%EUR 6.32
Terveystalo Oyj
Terveystalo Oyj Terveystalo Oyj Valor: 37893402
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.81%EUR 6.23
Siemens Healthineers AG
Siemens Healthineers AG Siemens Healthineers AG Valor: 40652181
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.76%EUR 44.66
Beiersdorf AG
Beiersdorf AG Beiersdorf AG Valor: 324660
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.70%EUR 85.26
BridgeBio Pharma Inc
BridgeBio Pharma Inc BridgeBio Pharma Inc Valor: 48204826
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.03%USD 74.29
Fresenius SE & Co. KGaA
Fresenius SE & Co. KGaA Fresenius SE & Co. KGaA Valor: 332902
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.18%EUR 52.48
Allogene Therapeutics Inc
Allogene Therapeutics Inc Allogene Therapeutics Inc Valor: 43756548
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-4.59%USD 1.04